Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4156-4180

  Yuan, Jing ^a   Venkatraman, Shankar ^a   Zheng, Yajun ^a   McKeever, Brian M ^a   Dillard, Lawrence W ^a   Singh, Suresh B ^a  

^a Vitae Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 W 51; 1 W51; 1 YM 2; 1 YM 4; 1 YM2; 1 YM4; 2 IRZ; 2 P 4J; 2 P4J; 2 PH 8; 2 PH8; 2 QMG; 2 QU 2; 2 QU 3; 2 QU2; 2 QU3; 2 QZL; 2 VJ 7; 2 VJ7; 2 VKM; 3 DM 6; 3 DM6; 3 IGB; 3 IXJ; 3 IXK; 3 K 5C; 3 K5C; 3 L 38; 3 L 59; 3 L38; 3 L59; 3 LPK; 4 AZY; 4 DH 6; 4 DH6; 4 DJU; 4 DJW; 4 DJY; 4 DUS; BETA SECRETASE 1 INHIBITOR; E 2609; ENZYME INHIBITOR; MK 8931; OM 992; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; LIGAND BINDING; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATENT; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BIOCATALYSIS; BLOOD-BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; CLINICAL TRIALS AS TOPIC; HUMANS; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84879067500     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301659n     Document Type: Review

References (149)

1. Wong, C. W.; Quaranta, V.; Glenner, G. G. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 8729-8732 (Pubitemid 16101117)
2. O'Brien, R. J.; Wong, P. C. Amyloid precursor protein processing and Alzheimer's disease Annu. Rev. Neurosci. 2011, 34, 185-204
3. Alzheimer's Disease Education and Referral Center, National Institutes on Aging. http://www.nia.nih.gov/alzheimers/topics/alzheimers-basics.
4. DeMattos, R. B.; Bales, K. R.; Cummins, D. J.; Paul, S. M.; Holtzman, D. M. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease Science 2002, 295, 2264-2267 (Pubitemid 34258840)
5. Hussain, I.; Powell, D.; Howlett, D. R.; Tew, D. G.; Meek, T. D.; Chapman, C.; Gloger, I. S.; Murphy, K. E.; Southan, C. D.; Ryan, D. M.; Smith, T. S.; Simmons, D. L.; Walsh, F. S.; Dingwall, C.; Christie, G. Identification of a novel aspartic protease (Asp 2) as beta-secretase Mol. Cell. Neurosci. 1999, 14, 419-427 (Pubitemid 30026585)
6. Yan, R.; Bienkowski, M. J.; Shuck, M. E.; Miao, H.; Tory, M. C.; Pauley, A. M.; Brashier, J. R.; Stratman, N. C.; Mathews, W. R.; Buhl, A. E.; Carter, D. B.; Tomasselli, A. G.; Parodi, L. A.; Heinrikson, R. L.; Gurney, M. E. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity Nature 1999, 402, 533-537
7. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE Science 1999, 286, 735-741
8. Sinha, S.; Anderson, J. P.; Barbour, R.; Basi, G. S.; Caccavello, R.; Davis, D.; Doan, M.; Dovey, H. F.; Frigon, N.; Hong, J.; Jacobson-Croak, K.; Jewett, N.; Keim, P.; Knops, J.; Lieberburg, I.; Power, M.; Tan, H.; Tatsuno, G.; Tung, J.; Schenk, D.; Seubert, P.; Suomensaari, S. M.; Wang, S.; Walker, D.; Zhao, J.; McConlogue, L.; John, V. Purification and cloning of amyloid precursor protein beta-secretase from human brain Nature 1999, 402, 537-540
9. Lin, X.; Koelsch, G.; Wu, S.; Downs, D.; Dashti, A.; Tang, J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 1456-1460 (Pubitemid 30118462)
10. Kandalepas, P. C.; Vassar, R. Identification and biology of beta-secretase J. Neurochem. 1111, 120 (Suppl. 1) 55-61
11. Jonsson, T.; Atwal, J. K.; Steinberg, S.; Snaedal, J.; Jonsson, P. V.; Bjornsson, S.; Stefansson, H.; Sulem, P.; Gudbjartsson, D.; Maloney, J.; Hoyte, K.; Gustafson, A.; Liu, Y.; Lu, Y.; Bhangale, T.; Graham, R. R.; Huttenlocher, J.; Bjornsdottir, G.; Andreassen, O. A.; Jonsson, E. G.; Palotie, A.; Behrens, T. W.; Magnusson, O. T.; Kong, A.; Thorsteinsdottir, U.; Watts, R. J.; Stefansson, K. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline Nature 2012, 488, 96-99
12. Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice Science 1996, 274, 99-102 (Pubitemid 26332733)
13. Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A. K.; Zhang, X. C.; Tang, J. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor Science 2000, 290, 150-153
14. Hong, L.; Turner, R. T., 3rd; Koelsch, G.; Shin, D.; Ghosh, A. K.; Tang, J. Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3 Biochemistry 2002, 41, 10963-10967 (Pubitemid 35001209)
15. Ali, A.; Bandaranayake, R. M.; Cai, Y.; King, N. M.; Kolli, M.; Mittal, S.; Murzycki, J. F.; Nalam, M. N.; Nalivaika, E. A.; Ozen, A.; Prabu-Jeyabalan, M. M.; Thayer, K.; Schiffer, C. A. Molecular basis for drug resistance in HIV-1 protease Viruses 2009, 2, 2509-2535
16. RCSB PDB. http://www.rcsb.org/pdb. As of Mar 4, 2013, at 2.27 p.m. EST, there are 235 BACE1 X-ray structures using the key word BACE1 followed by selecting entries with 95% sequence similarity to BACE1.
17. Percent identity of the target sequences was calculated with BACE1 sequence (accession code P56817) from NCBI using sequence database search program BLASTP (version 2.2.27) against the nonredundant protein sequences database with keyword organism=Homo sapiens (taxid:9606) on Jan 27, 2013 (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins&PROGRAM= blastp&BLAST-PROGRAMS=blastp&QUERY=P56817.2&LINK-LOC= protein&PAGE-TYPE=BlastSearch).
18. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834 (Pubitemid 351304691)
19. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 49, 7559-7583 (Pubitemid 46033646)
20. Broccatelli, F.; Larregieu, C. A.; Cruciani, G.; Oprea, T. I.; Benet, L. Z. Improving the prediction of the brain disposition for orally administered drugs using BDDCS Adv. Drug Delivery Rev. 2012, 64, 95-109
21. Mahar Doan, K. M.; Humphreys, J. E.; Webster, L. O.; Wring, S. A.; Shampine, L. J.; Serabjit-Singh, C. J.; Adkison, K. K.; Polli, J. W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J. Pharmacol. Exp. Ther. 2002, 303, 1029-1037 (Pubitemid 35424386)
22. Fridén, M.; Winiwarter, S.; Jerndal, G.; Bengtsson, O.; Wan, H.; Bredberg, U.; Hammarlund-Udenaes, M.; Antonsson, M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids J. Med. Chem. 2009, 52, 6233-6243
23. Di, L.; Rong, H.; Feng, B. Demystifying brain penetration in central nervous system drug discovery J. Med. Chem. 2013, 56, 2-12
24. Seelig, A.; Landwojtowicz, E. Structure-activity relationship of P-glycoprotein substrates and modifiers Eur. J. Pharm. Sci. 2000, 12, 31-40
25. Penzotti, J. E.; Lamb, M. L.; Evensen, E.; Grootenhuis, P. D. J. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein J. Med. Chem. 2002, 45, 1737-1740 (Pubitemid 34415368)
26. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 2001, 299, 620-628 (Pubitemid 32979675)
27. Ha, S. N.; Hochman, J.; Sheridan, R. P. Mini review on molecular modeling of P-glycoprotein (Pgp) Curr. Top. Med. Chem. 2007, 7, 1525-1529 (Pubitemid 47618065)
28. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E. C. A.; Kasman, I. N.; LaPerle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1a/1b knockout mouse model Drug Metab. Dispos. 2005, 33, 165-174 (Pubitemid 40023528)
29. Yamazaki, M.; Neway, W. E.; Ohe, T.; Chen, I. W.; Rowe, J. F.; Hochman, J. H.; Chiba, M.; Lin, J. H. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results J. Pharmacol. Exp. Ther. 2001, 296, 723-735 (Pubitemid 32187340)
30. Tang, C.; Kuo, Y.; Pudvah, N. T.; Ellis, J. D.; Michener, M. S.; Egbertson, M.; Graham, S. L.; Cook, J. J.; Hochman, J. H.; Prueksaritanont, T. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys Biochem. Pharmacol. 2009, 78, 642-647
31. Maurer, T. S.; DeBartolo, D. B.; Tess, D. A.; Scott, D. O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice Drug Metab. Dispos. 2005, 33, 175-181 (Pubitemid 40023529)
32. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug. Delivery Rev. 2001, 46, 3-26 (Pubitemid 33653411)
33. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 (Pubitemid 350042396)
34. Waring, M. J. Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower logD limits based on permeability Bioorg. Med. Chem. Lett. 2009, 19, 2844-2851
35. Gleeson, P.; Bravi, G.; Modi, S.; Lowe, D. ADMET rules of thumb II: a comparison of the effects of common substituents on a range of ADMET parameters Bioorg. Med. Chem. 2009, 17, 5906-5919
36. Hitchcock, S. A. Structural modifications that alter the P-glycoprotein efflux properties of compounds J. Med. Chem. 2012, 55, 4877-4895
37. Egan, W. J.; Merz, K. M., Jr.; Baldwin, J. J. Prediction of drug absorption using multivariate statistics J. Med. Chem. 2000, 43, 3867-3877
38. Eriksen, J. L.; Murphy, M. P.; Head, E. Pharmacological Models for Preclinical Testing: From Mouse to Dog to Nonhuman Primates. In BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease; Varghese, J., Ed.; John Wiley & Sons: Hoboken, NJ, 2010; pp 159-175.
39. Kang, J.; Lemaire, H.-G.; Unterbeck, A.; Salbaum, J. M.; Masters, C. L.; Grzeschik, K.-H.; Multhaup, G.; Beyreuther, K.; Müller-Hill, B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor Nature 1987, 325, 733-736 (Pubitemid 17054046)
40. Yamada, T.; Sasaki, H.; Furuya, H.; Miyata, T.; Goto, I.; Sakaki, Y. Complementary DNA for the mouse homolog of the human amyloid beta protein precursor Biochem. Biophys. Res. Commun. 1987, 149, 665-671 (Pubitemid 18023031)
41. Shivers, B. D.; Hilbich, C.; Multhaup, G.; Salbaum, M.; Beyreuther, K.; Seeburg, P. H. Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact EMBO J. 1988, 7, 1365-1370
42. Sarasa, L.; Gallego, C.; Monleon, I.; Olvera, A.; Canudas, J.; Montanes, M.; Pesini, P.; Sarasa, M. Cloning, sequencing and expression in the dog of the main amyloid precursor protein isoforms and some of the enzymes related with their processing Neuroscience 2010, 171, 1091-1101
43. Nakata, M. Sequence analysis and chromosomal mapping of presenilin-1 and amyloid precursor protein genes in dogs. Submitted to the EMBL/GenBank/DDBJ databases, 2003.
44. Pandey, S.; Maudhoo, M. D.; Guda, C.; Ferguson, B.; Fox, H.; Norgren, R. B. De novo assembly of the rhesus macaque transcriptome from NextGen mRNA sequences. Submitted to the EMBL/GenBank/DDBJ databases, 2012.
45. Lerchner, A.; Machauer, R.; Betschart, C.; Veenstra, S.; Rueeger, H.; McCarthy, C.; Tintelnot-Blomley, M.; Jaton, A.-L.; Rabe, S.; Desrayaud, S.; Enz, A.; Staufenbiel, M.; Paganetti, P.; Rondeau, J.-M.; Neumann, U. Macrocyclic BACE-1 inhibitors acutely reduce Aβ in brain after po application Bioorg. Med. Chem. Lett. 2010, 20, 603-607
46. Sankaranarayanan, S.; Holahan, M. A.; Colussi, D.; Crouthamel, M. C.; Devanarayan, V.; Ellis, J.; Espeseth, A.; Gates, A. T.; Graham, S. L.; Gregro, A. R.; Hazuda, D.; Hochman, J. H.; Holloway, K.; Jin, L.; Kahana, J.; Lai, M. T.; Lineberger, J.; McGaughey, G.; Moore, K. P.; Nantermet, P.; Pietrak, B.; Price, E. A.; Rajapakse, H.; Stauffer, S.; Steinbeiser, M. A.; Seabrook, G.; Selnick, H. G.; Shi, X. P.; Stanton, M. G.; Swestock, J.; Tugusheva, K.; Tyler, K. X.; Vacca, J. P.; Wong, J.; Wu, G.; Xu, M.; Cook, J. J.; Simon, A. J. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates J. Pharmacol. Exp. Ther. 2009, 328, 131-140
47. Dineen, T. A.; Weiss, M. M.; Williamson, T.; Acton, P.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Dunn, R. T.; Esmay, J.; Graceffa, R. F.; Harried, S. S.; Hickman, D.; Hitchcock, S. A.; Horne, D. B.; Huang, H.; Imbeah-Ampiah, R.; Judd, T.; Kaller, M. R.; Kreiman, C. R.; La, D. S.; Li, V.; Lopez, P.; Louie, S.; Monenschein, H.; Nguyen, T. T.; Pennington, L. D.; Miguel, T. S.; Sickmier, E. A.; Vargas, H. M.; Wahl, R. C.; Wen, P. H.; Whittington, D. A.; Wood, S.; Xue, Q.; Yang, B. H.; Patel, V. F.; Zhong, W. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors J. Med. Chem. 2012, 55, 9025-9044
48. Weiss, M. M.; Williamson, T.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Dineen, T. A.; Esmay, J.; Graceffa, R. F.; Harried, S. S.; Hickman, D.; Hitchcock, S. A.; Horne, D. B.; Huang, H.; Imbeah-Ampiah, R.; Judd, T.; Kaller, M. R.; Kreiman, C. R.; La, D. S.; Li, V.; Lopez, P.; Louie, S.; Monenschein, H.; Nguyen, T. T.; Pennington, L. D.; Rattan, C.; San Miguel, T.; Sickmier, E. A.; Wahl, R. C.; Wen, P. H.; Wood, S.; Xue, Q.; Yang, B. H.; Patel, V. F.; Zhong, W. Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid J. Med. Chem. 2012, 55, 9009-9024
49. Shimizu, H.; Tosaki, A.; Kaneko, K.; Hisano, T.; Sakurai, T.; Nukina, N. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production Mol. Cell. Biol. 2008, 28, 3663-3671 (Pubitemid 351732903)
50. Hong, L.; Tang, J. Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis Biochemistry 2004, 43, 4689-4695 (Pubitemid 38509089)
51. Gorfe, A. A.; Caflisch, A. Functional plasticity in the substrate binding site of beta-secretase Structure 2005, 13, 1487-1498 (Pubitemid 41427588)
52. Spronk, S. A.; Carlson, H. A. The role of tyrosine 71 in modulating the flap conformations of BACE1 Proteins 2011, 79, 2247-2259
53. Tice, C. M.; Singh, S. B. Evolution of Diverse Classes of Renin Inhibitors through the Years. In Aspartic Acid Proteases as Therapeutic Targets; Ghosh, A. K., Ed.; Wiley-VCH: Weinheim, Germany, 2011; pp 297-324.
54. McGaughey, G. B.; Colussi, D.; Graham, S. L.; Lai, M.-T.; Munshi, S. K.; Nantermet, P. G.; Pietrak, B.; Rajapakse, H. A.; Selnick, H. G.; Stauffer, S. R.; Holloway, M. K. β-Secretase (BACE-1) inhibitors: accounting for 10s loop flexibility using rigid active sites Bioorg. Med. Chem. Lett. 2007, 17, 1117-1121 (Pubitemid 46177599)
55. McGaughey, G. B.; Holloway, M. K. Structure-guided design of β-secretase (BACE-1) inhibitors Expert Opin. Drug Discovery 2007, 2, 1129-1138 (Pubitemid 47354335)
56. Suguna, K.; Padlan, E. A.; Smith, C. W.; Carlson, W. D.; Davies, D. R. Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7009-7013
57. Davies, D. R. The structure and function of the aspartic proteinases Annu. Rev. Biophys. Biophys. Chem. 1990, 19, 189-215 (Pubitemid 20205623)
58. Eder, J.; Hommel, U.; Cumin, F.; Martoglio, B.; Gerhartz, B. Aspartic proteases in drug discovery Curr. Pharm. Des. 2007, 13, 271-285 (Pubitemid 46085279)
59. Coates, L.; Tuan, H.-F.; Tomanicek, S.; Kovalevsky, A.; Mustyakimov, M.; Erskine, P.; Cooper, J. The catalytic mechanism of an aspartic proteinase explored with neutron and X-ray diffraction J. Am. Chem. Soc. 2008, 130, 7235-7237 (Pubitemid 351813210)
60. Toulokhonova, L.; Metzler, W. J.; Witmer, M. R.; Copeland, R. A.; Marcinkeviciene, J. Kinetic studies on β-site amyloid precursor protein-cleaving enzyme (BACE) J. Biol. Chem. 2003, 278, 4582-4589 (Pubitemid 36800955)
61. Rajamani, R.; Reynolds, C. H. Modeling the protonation states of the catalytic aspartates in beta-secretase J. Med. Chem. 2004, 47, 5159-5166 (Pubitemid 39314913)
62. Yu, N.; Hayik, S. A.; Wang, B.; Liao, N.; Reynolds, C. H.; Merz, K. M. Assigning the protonation states of the key aspartates in β-secretase using QM/MM X-ray structure refinement J. Chem. Theory Comput. 2006, 2, 1057-1069
63. Domínguez, J. L.; Christopeit, T.; Villaverde, M. C.; Gossas, T.; Otero, J. M.; Nyström, S.; Baraznenok, V.; Lindström, E.; Danielson, U. H.; Sussman, F. Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1 Biochemistry 2010, 49, 7255-7263
64. Kacker, P.; Masetti, M.; Mangold, M.; Bottegoni, G.; Cavalli, A. Combining dyad protonation and active site plasticity in BACE-1 structure-based drug design J. Chem. Inf. Model. 2012, 52, 1079-1085
65. Probst, G.; Xu, Y. Z. Small-molecule BACE1 inhibitors: a patent literature review (2006-2011) Expert Opin. Ther. Pat. 2012, 22, 511-540
66. Cooper, J. B. Structure-Based Drug Design Strategies for Inhibition of Aspartic Proteinases. In Aspartic Acid Proteases as Therapeutic Targets; Ghosh, A. K., Ed.; Wiley-VCH: Weinheim, Germany, 2011; pp 71-105.
67. Virgil, S. C. First-Generation HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. In Aspartic Acid Proteases as Therapeutic Targets; Ghosh, A. K., Ed.; Wiley-VCH: Weinheim, Germany, 2011; pp 139-168.
68. Turner, R. T.; Hong, L.; Koelsch, G.; Ghosh, A. K.; Tang, J. Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (β-secretase) Biochemistry 2004, 44, 105-112 (Pubitemid 40095711)
69. Hanessian, S.; Yun, H.; Hou, Y.; Yang, G.; Bayrakdarian, M.; Therrien, E.; Moitessier, N.; Roggo, S.; Veenstra, S.; Tintelnot-Blomley, M.; Rondeau, J.-M.; Ostermeier, C.; Strauss, A.; Ramage, P.; Paganetti, P.; Neumann, U.; Betschart, C. Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics J. Med. Chem. 2005, 48, 5175-5190 (Pubitemid 41113905)
70. Ghosh, A. K.; Kumaragurubaran, N.; Hong, L.; Kulkarni, S.; Xu, X.; Miller, H. B.; Srinivasa Reddy, D.; Weerasena, V.; Turner, R.; Chang, W.; Koelsch, G.; Tang, J. Potent memapsin 2 (β-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation Bioorg. Med. Chem. Lett. 2008, 18, 1031-1036 (Pubitemid 351179350)
71. Ghosh, A. K.; Kumaragurubaran, N.; Hong, L.; Kulkarni, S. S.; Xu, X.; Chang, W.; Weerasena, V.; Turner, R.; Koelsch, G.; Bilcer, G.; Tang, J. Design, synthesis, and X-ray structure of potent memapsin 2 (β-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands J. Med. Chem. 2007, 50, 2399-2407 (Pubitemid 46799251)
72. Bäck, M.; Nyhlén, J.; Kvarnström, I.; Appelgren, S.; Borkakoti, N.; Jansson, K.; Lindberg, J.; Nyström, S.; Hallberg, A.; Rosenquist, S.; Samuelsson, B. Design, synthesis and SAR of potent statine-based BACE-1 inhibitors: exploration of P1 phenoxy and benzyloxy residues Bioorg. Med. Chem. 2008, 16, 9471-9486
73. Björklund, C.; Adolfsson, H.; Jansson, K.; Lindberg, J.; Vrang, L.; Hallberg, A.; Rosenquist, Ã. s.; Samuelsson, B. Discovery of potent BACE-1 inhibitors containing a new hydroxyethylene (HE) scaffold: exploration of P1′ alkoxy residues and an aminoethylene (AE) central core Bioorg. Med. Chem. 2010, 18, 1711-1723
74. Björklund, C.; Oscarson, S.; Benkestock, K.; Borkakoti, N.; Jansson, K.; Lindberg, J.; Vrang, L.; Hallberg, A.; Rosenquist, A.; Samuelsson, B. Design and synthesis of potent and selective BACE-1 inhibitors J. Med. Chem. 2010, 53, 1458-1464
75. WaÌŠngsell, F.; Gustafsson, K.; Kvarnström, I.; Borkakoti, N.; Edlund, M.; Jansson, K.; Lindberg, J.; Hallberg, A.; Rosenquist, A.; Samuelsson, B. Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core Eur. J. Med. Chem. 2010, 45, 870-882
76. Ghosh, A. K.; Devasamudram, T.; Hong, L.; DeZutter, C.; Xu, X.; Weerasena, V.; Koelsch, G.; Bilcer, G.; Tang, J. Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (β-secretase) Bioorg. Med. Chem. Lett. 2005, 15, 15-20 (Pubitemid 39575774)
77. Hanessian, S.; Shao, Z.; Betschart, C.; Rondeau, J.-M.; Neumann, U.; Tintelnot-Blomley, M. Structure-based design and synthesis of novel P2/P3 modified, non-peptidic β-secretase (BACE-1) inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1924-1927
78. Machauer, R.; Veenstra, S.; Rondeau, J.-M.; Tintelnot-Blomley, M.; Betschart, C.; Neumann, U.; Paganetti, P. Structure-based design and synthesis of macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 1361-1365
79. Iserloh, U.; Cumming, J. N. Peptidomimetic BACE1 Inhibitors for Treatment of Alzheimer's Disease: Design and Evolution. In Aspartic Acid Proteases as Therapeutic Targets; Ghosh, A. K., Ed.; Wiley-VCH: Weinheim, Germany, 2010; pp 441-479.
80. Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C. W.; Yon, J. Apo and inhibitor complex structures of BACE (β-secretase) J. Mol. Biol. 2004, 343, 407-416 (Pubitemid 39296874)
81. Maillard, M. C.; Hom, R. K.; Benson, T. E.; Moon, J. B.; Mamo, S.; Bienkowski, M.; Tomasselli, A. G.; Woods, D. D.; Prince, D. B.; Paddock, D. J.; Emmons, T. L.; Tucker, J. A.; Dappen, M. S.; Brogley, L.; Thorsett, E. D.; Jewett, N.; Sinha, S.; John, V. Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human β-secretase J. Med. Chem. 2007, 50, 776-781 (Pubitemid 46332990)
82. Stachel, S. J.; Coburn, C. A.; Steele, T. G.; Crouthamel, M.-C.; Pietrak, B. L.; Lai, M.-T.; Holloway, M. K.; Munshi, S. K.; Graham, S. L.; Vacca, J. P. Conformationally biased P3 amide replacements of β-secretase inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 641-644 (Pubitemid 43014850)
83. Freskos, J. N.; Fobian, Y. M.; Benson, T. E.; Bienkowski, M. J.; Brown, D. L.; Emmons, T. L.; Heintz, R.; Laborde, A.; McDonald, J. J.; Mischke, B. V.; Molyneaux, J. M.; Moon, J. B.; Mullins, P. B.; Prince, D. B.; Paddock, D. J.; Tomasselli, A. G.; Winterrowd, G. Design of potent inhibitors of human β-secretase. Part 1 Bioorg. Med. Chem. Lett. 2007, 17, 73-77 (Pubitemid 44959985)
84. Freskos, J. N.; Fobian, Y. M.; Benson, T. E.; Moon, J. B.; Bienkowski, M. J.; Brown, D. L.; Emmons, T. L.; Heintz, R.; Laborde, A.; McDonald, J. J.; Mischke, B. V.; Molyneaux, J. M.; Mullins, P. B.; Prince, D. B.; Paddock, D. J.; Tomassellia, A. G.; Winterrowd, G. Design of potent inhibitors of human β-secretase. Part 2 Bioorg. Med. Chem. Lett. 2007, 17, 78-81 (Pubitemid 44959984)
85. Probst, G. D.; Bowers, S.; Sealy, J. M.; Stupi, B.; Dressen, D.; Jagodzinska, B. M.; Aquino, J.; Gailunas, A.; Truong, A. P.; Tso, L.; Xu, Y.-Z.; Hom, R. K.; John, V.; Tung, J. S.; Pleiss, M. A.; Tucker, J. A.; Konradi, A. W.; Sham, H. L.; Jagodzinski, J.; Tóth, G.; Brecht, E.; Yao, N.; Pan, H.; Lin, M.; Artis, D. R.; Ruslim, L.; Bova, M. P.; Sinha, S.; Yednock, T. A.; Gauby, S.; Zmolek, W.; Quinn, K. P.; Sauer, J.-M. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region Bioorg. Med. Chem. Lett. 2010, 20, 6034-6039
86. Sealy, J. M.; Truong, A. P.; Tso, L.; Probst, G. D.; Aquino, J.; Hom, R. K.; Jagodzinska, B. M.; Dressen, D.; Wone, D. W. G.; Brogley, L.; John, V.; Tung, J. S.; Pleiss, M. A.; Tucker, J. A.; Konradi, A. W.; Dappen, M. S.; Tóth, G.; Pan, H.; Ruslim, L.; Miller, J.; Bova, M. P.; Sinha, S.; Quinn, K. P.; Sauer, J.-M. Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1′ substituents Bioorg. Med. Chem. Lett. 2009, 19, 6386-6391
87. Truong, A. P.; Probst, G. D.; Aquino, J.; Fang, L.; Brogley, L.; Sealy, J. M.; Hom, R. K.; Tucker, J. A.; John, V.; Tung, J. S.; Pleiss, M. A.; Konradi, A. W.; Sham, H. L.; Dappen, M. S.; Tóth, G.; Yao, N.; Brecht, E.; Pan, H.; Artis, D. R.; Ruslim, L.; Bova, M. P.; Sinha, S.; Yednock, T. A.; Zmolek, W.; Quinn, K. P.; Sauer, J.-M. Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2′ substituents Bioorg. Med. Chem. Lett. 2010, 20, 4789-4794
88. Kortum, S. W.; Benson, T. E.; Bienkowski, M. J.; Emmons, T. L.; Prince, D. B.; Paddock, D. J.; Tomasselli, A. G.; Moon, J. B.; LaBorde, A.; TenBrink, R. E. Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE1 Bioorg. Med. Chem. Lett. 2007, 17, 3378-3383 (Pubitemid 46819025)
89. Iserloh, U.; Wu, Y.; Cumming, J. N.; Pan, J.; Wang, L. Y.; Stamford, A. W.; Kennedy, M. E.; Kuvelkar, R.; Chen, X.; Parker, E. M.; Strickland, C.; Voigt, J. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 414-417
90. Iserloh, U.; Pan, J.; Stamford, A. W.; Kennedy, M. E.; Zhang, Q.; Zhang, L.; Parker, E. M.; McHugh, N. A.; Favreau, L.; Strickland, C.; Voigt, J. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor Bioorg. Med. Chem. Lett. 2008, 18, 418-422
91. Cumming, J. N.; Le, T. X.; Babu, S.; Carroll, C.; Chen, X.; Favreau, L.; Gaspari, P.; Guo, T.; Hobbs, D. W.; Huang, Y.; Iserloh, U.; Kennedy, M. E.; Kuvelkar, R.; Li, G.; Lowrie, J.; McHugh, N. A.; Ozgur, L.; Pan, J.; Parker, E. M.; Saionz, K.; Stamford, A. W.; Strickland, C.; Tadesse, D.; Voigt, J.; Wang, L.; Wu, Y.; Zhang, L.; Zhang, Q. Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 3236-3241 (Pubitemid 351718333)
92. Cumming, J.; Babu, S.; Huang, Y.; Carrol, C.; Chen, X.; Favreau, L.; Greenlee, W.; Guo, T.; Kennedy, M.; Kuvelkar, R.; Le, T.; Li, G.; McHugh, N.; Orth, P.; Ozgur, L.; Parker, E.; Saionz, K.; Stamford, A.; Strickland, C.; Tadesse, D.; Voigt, J.; Zhang, L.; Zhang, Q. Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization Bioorg. Med. Chem. Lett. 2010, 20, 2837-2842
93. Clarke, B.; Demont, E.; Dingwall, C.; Dunsdon, R.; Faller, A.; Hawkins, J.; Hussain, I.; MacPherson, D.; Maile, G.; Matico, R.; Milner, P.; Mosley, J.; Naylor, A.; O'Brien, A.; Redshaw, S.; Riddell, D.; Rowland, P.; Soleil, V.; Smith, K. J.; Stanway, S.; Stemp, G.; Sweitzer, S.; Theobald, P.; Vesey, D.; Walter, D. S.; Ward, J.; Wayne, G. BACE-1 inhibitors part 2: Identification of hydroxyethylamines (HEAs) with reduced peptidic character Bioorg. Med. Chem. Lett. 2008, 18, 1017-1021 (Pubitemid 351179342)
94. Beswick, P.; Charrier, N.; Clarke, B.; Demont, E.; Dingwall, C.; Dunsdon, R.; Faller, A.; Gleave, R.; Hawkins, J.; Hussain, I.; Johnson, C. N.; MacPherson, D.; Maile, G.; Matico, R.; Milner, P.; Mosley, J.; Naylor, A.; O'Brien, A.; Redshaw, S.; Riddell, D.; Rowland, P.; Skidmore, J.; Soleil, V.; Smith, K. J.; Stanway, S.; Stemp, G.; Stuart, A.; Sweitzer, S.; Theobald, P.; Vesey, D.; Walter, D. S.; Ward, J.; Wayne, G. BACE-1 inhibitors part 3: Identification of hydroxyethylamines (HEAs) with nanomolar potency in cells Bioorg. Med. Chem. Lett. 2008, 18, 1022-1026 (Pubitemid 351179343)
95. Hussain, I.; Hawkins, J.; Harrison, D.; Hille, C.; Wayne, G.; Cutler, L.; Buck, T.; Walter, D.; Demont, E.; Howes, C.; Naylor, A.; Jeffrey, P.; Gonzalez, M. I.; Dingwall, C.; Michel, A.; Redshaw, S.; Davis, J. B. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid-β production in vivo J. Neurochem. 2007, 100, 802-809 (Pubitemid 46095629)
96. Charrier, N.; Clarke, B.; Cutler, L.; Demont, E.; Dingwall, C.; Dunsdon, R.; East, P.; Hawkins, J.; Howes, C.; Hussain, I.; Jeffrey, P.; Maile, G.; Matico, R.; Mosley, J.; Naylor, A.; O'Brien, A.; Redshaw, S.; Rowland, P.; Soleil, V.; Smith, K. J.; Sweitzer, S.; Theobald, P.; Vesey, D.; Walter, D. S.; Wayne, G. Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability J. Med. Chem. 2008, 51, 3313-3317 (Pubitemid 351821890)
97. Charrier, N.; Clarke, B.; Cutler, L.; Demont, E.; Dingwall, C.; Dunsdon, R.; Hawkins, J.; Howes, C.; Hubbard, J.; Hussain, I.; Maile, G.; Matico, R.; Mosley, J.; Naylor, A.; O'Brien, A.; Redshaw, S.; Rowland, P.; Soleil, V.; Smith, K. J.; Sweitzer, S.; Theobald, P.; Vesey, D.; Walter, D. S.; Wayne, G. Second generation of BACE-1 inhibitors part 3: towards non hydroxyethylamine transition state mimetics Bioorg. Med. Chem. Lett. 2009, 19, 3674-3678
98. Charrier, N.; Clarke, B.; Cutler, L.; Demont, E.; Dingwall, C.; Dunsdon, R.; Hawkins, J.; Howes, C.; Hubbard, J.; Hussain, I.; Maile, G.; Matico, R.; Mosley, J.; Naylor, A.; O'Brien, A.; Redshaw, S.; Rowland, P.; Soleil, V.; Smith, K. J.; Sweitzer, S.; Theobald, P.; Vesey, D.; Walter, D. S.; Wayne, G. Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics Bioorg. Med. Chem. Lett. 2009, 19, 3664-3668
99. Charrier, N.; Clarke, B.; Demont, E.; Dingwall, C.; Dunsdon, R.; Hawkins, J.; Hubbard, J.; Hussain, I.; Maile, G.; Matico, R.; Mosley, J.; Naylor, A.; O'Brien, A.; Redshaw, S.; Rowland, P.; Soleil, V.; Smith, K. J.; Sweitzer, S.; Theobald, P.; Vesey, D.; Walter, D. S.; Wayne, G. Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent Bioorg. Med. Chem. Lett. 2009, 19, 3669-3673
100. Marcin, L. R.; Higgins, M. A.; Zusi, F. C.; Zhang, Y.; Dee, M. F.; Parker, M. F.; Muckelbauer, J. K.; Camac, D. M.; Morin, P. E.; Ramamurthy, V.; Tebben, A. J.; Lentz, K. A.; Grace, J. E.; Marcinkeviciene, J. A.; Kopcho, L. M.; Burton, C. R.; Barten, D. M.; Toyn, J. H.; Meredith, J. E.; Albright, C. F.; Bronson, J. J.; Macor, J. E.; Thompson, L. A. Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1 Bioorg. Med. Chem. Lett. 2011, 21, 537-541
101. Thompson, L. A.; Shi, J.; Decicco, C. P.; Tebben, A. J.; Olson, R. E.; Boy, K. M.; Guernon, J. M.; Good, A. C.; Liauw, A.; Zheng, C.; Copeland, R. A.; Combs, A. P.; Trainor, G. L.; Camac, D. M.; Muckelbauer, J. K.; Lentz, K. A.; Grace, J. E.; Burton, C. R.; Toyn, J. H.; Barten, D. M.; Marcinkeviciene, J.; Meredith, J. E.; Albright, C. F.; Macor, J. E. Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 6909-6915
102. Boy, K. M.; Guernon, J. M.; Shi, J.; Toyn, J. H.; Meredith, J. E.; Barten, D. M.; Burton, C. R.; Albright, C. F.; Marcinkeviciene, J.; Good, A. C.; Tebben, A. J.; Muckelbauer, J. K.; Camac, D. M.; Lentz, K. A.; Bronson, J. J.; Olson, R. E.; Macor, J. E.; Thompson, L. A., III. Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE) Bioorg. Med. Chem. Lett. 2011, 21, 6916-6924
103. Park, H.; Min, K.; Kwak, H.-S.; Koo, K. D.; Lim, D.; Seo, S.-W.; Choi, J.-U.; Platt, B.; Choi, D.-Y. Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives Bioorg. Med. Chem. Lett. 2008, 18, 2900-2904 (Pubitemid 351622045)
104. Rueeger, H.; Rondeau, J.-M.; McCarthy, C.; Mobitz, H.; Tintelnot-Blomley, M.; Neumann, U.; Desrayaud, S. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 1942-1947
105. Kaller, M. R.; Halrried, S. S.; Albrecht, B.; Amarante, P.; Babu-Khan, S.; Bartberger, M. D.; Brown, J.; Brown, R.; Chen, K.; Cheng, Y.; Citron, M.; Croghan, M. D.; Graceffa, R.; Hickman, D.; Judd, T.; Kriemen, C.; La, D.; Li, V.; Lopez, P.; Luo, Y.; Masse, C.; Monenschein, H.; Nguyen, T.; Pennington, L. D.; Miguel, T. S.; Sickmier, E. A.; Wahl, R. C.; Weiss, M. M.; Wen, P. H.; Williamson, T.; Wood, S.; Xue, M.; Yang, B.; Zhang, J.; Patel, V.; Zhong, W.; Hitchcock, S. A potent and orally efficacious, hydroxyethylamine-based inhibitor of β-secretase ACS Med. Chem. Lett. 2012, 3, 886-891
106. Machauer, R.; Laumen, K.; Veenstra, S.; Rondeau, J.-M.; Tintelnot-Blomley, M.; Betschart, C.; Jaton, A.-L.; Desrayaud, S.; Staufenbiel, M.; Rabe, S.; Paganetti, P.; Neumann, U. Macrocyclic peptidomimetic β-secretase (BACE-1) inhibitors with activity in vivo Bioorg. Med. Chem. Lett. 2009, 19, 1366-1370
107. Jia, L.; Simpson, R. D.; Yuan, J.; Xu, Z.; Zhao, W.; Cacatian, S.; Tice, C. M.; Guo, J.; Ishchenko, A.; Singh, S. B.; Wu, Z.; McKeever, B. M.; Bukhtiyarov, Y.; Johnson, J. A.; Doe, C. P.; Harrison, R. K.; McGeehan, G. M.; Dillard, L. W.; Baldwin, J. J.; Claremon, D. A. Discovery of VTP-27999, an alkyl
108. Yang, W.; Lu, W.; Lu, Y.; Zhong, M.; Sun, J.; Thomas, A. E.; Wilkinson, J. M.; Fucini, R. V.; Lam, M.; Randal, M.; Shi, X.-P.; Jacobs, J. W.; McDowell, R. S.; Gordon, E. M.; Ballinger, M. D. Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1 J. Med. Chem. 2006, 49, 839-842 (Pubitemid 43221630)
109. Stauffer, S. R.; Stanton, M. G.; Gregro, A. R.; Steinbeiser, M. A.; Shaffer, J. R.; Nantermet, P. G.; Barrow, J. C.; Rittle, K. E.; Collusi, D.; Espeseth, A. S.; Lai, M.-T.; Pietrak, B. L.; Holloway, M. K.; McGaughey, G. B.; Munshi, S. K.; Hochman, J. H.; Simon, A. J.; Selnick, H. G.; Graham, S. L.; Vacca, J. P. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind β-secretase in a N-terminal 10s-loop down conformation Bioorg. Med. Chem. Lett. 2007, 17, 1788-1792 (Pubitemid 46274326)
110. Rajapakse, H. A.; Nantermet, P. G.; Selnick, H. G.; Munshi, S.; McGaughey, G. B.; Lindsley, S. R.; Young, M. B.; Lai, M.-T.; Espeseth, A. S.; Shi, X.-P.; Colussi, D.; Pietrak, B.; Crouthamel, M.-C.; Tugusheva, K.; Huang, Q.; Xu, M.; Simon, A. J.; Kuo, L.; Hazuda, D. J.; Graham, S.; Vacca, J. P. Discovery of oxadiazoyl tertiary carbinamine inhibitors of β-secretase (BACE-1) J. Med. Chem. 2006, 49, 7270-7273 (Pubitemid 44913387)
111. Lindsley, S. R.; Moore, K. P.; Rajapakse, H. A.; Selnick, H. G.; Young, M. B.; Zhu, H.; Munshi, S.; Kuo, L.; McGaughey, G. B.; Colussi, D.; Crouthamel, M.-C.; Lai, M.-T.; Pietrak, B.; Price, E. A.; Sankaranarayanan, S.; Simon, A. J.; Seabrook, G. R.; Hazuda, D. J.; Pudvah, N. T.; Hochman, J. H.; Graham, S. L.; Vacca, J. P.; Nantermet, P. G. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 4057-4061 (Pubitemid 46920916)
112. Moore, K. P.; Zhu, H.; Rajapakse, H. A.; McGaughey, G. B.; Colussi, D.; Price, E. A.; Sankaranarayanan, S.; Simon, A. J.; Pudvah, N. T.; Hochman, J. H.; Allison, T.; Munshi, S. K.; Graham, S. L.; Vacca, J. P.; Nantermet, P. G. Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 5831-5835 (Pubitemid 47446223)
113. 2NH] reduced amide isosteres Bioorg. Med. Chem. Lett. 2006, 16, 3635-3638 (Pubitemid 44137227)
114. Barrow, J. C.; Rittle, K. E.; Ngo, P. L.; Selnick, H. G.; Graham, S. L.; Pitzenberger, S. M.; McGaughey, G. B.; Colussi, D.; Lai, M.-T.; Huang, Q.; Tugusheva, K.; Espeseth, A. S.; Simon, A. J.; Munshi, S. K.; Vacca, J. P. Design and synthesis of 2,3,5-substituted imidazolidin-4-one inhibitors of BACE-1 ChemMedChem 2007, 2, 995-999
115. Fobare, W. F.; Solvibile, W. R.; Robichaud, A. J.; Malamas, M. S.; Manas, E.; Turner, J.; Hu, Y.; Wagner, E.; Chopra, R.; Cowling, R.; Jin, G.; Bard, J. Thiophene substituted acylguanidines as BACE1 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 5353-5356 (Pubitemid 47391283)
116. Cole, D. C.; Manas, E. S.; Stock, J. R.; Condon, J. S.; Jennings, L. D.; Aulabaugh, A.; Chopra, R.; Cowling, R.; Ellingboe, J. W.; Fan, K. Y.; Harrison, B. L.; Hu, Y.; Jacobsen, S.; Jin, G.; Lin, L.; Lovering, F. E.; Malamas, M. S.; Stahl, M. L.; Strand, J.; Sukhdeo, M. N.; Svenson, K.; Turner, M. J.; Wagner, E.; Wu, J.; Zhou, P.; Bard, J. Acylguanidines as small-molecule β-secretase inhibitors J. Med. Chem. 2006, 49, 6158-6161
117. Malamas, M. S.; Barnes, K.; Hui, Y.; Johnson, M.; Lovering, F.; Condon, J.; Fobare, W.; Solvibile, W.; Turner, J.; Hu, Y.; Manas, E. S.; Fan, K.; Olland, A.; Chopra, R.; Bard, J.; Pangalos, M. N.; Reinhart, P.; Robichaud, A. J. Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors Biochemistry 2010, 20, 2068-2073
118. Malamas, M. S.; Erdei, J.; Gunawan, I.; Barnes, K.; Johnson, M.; Hui, Y.; Turner, J.; Hu, Y.; Wagner, E.; Fan, K.; Olland, A.; Bard, J.; Robichaud, A. J. Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors J. Med. Chem. 2009, 52, 6314-6323
119. Malamas, M. S.; Barnes, K.; Johnson, M.; Hui, Y.; Zhou, P.; Turner, J.; Hu, Y.; Wagner, E.; Fan, K.; Chopra, R.; Olland, A.; Bard, J.; Pangalos, M.; Reinhart, P.; Robichaud, A. J. Di-substituted pyridinyl aminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors Bioorg. Med. Chem. 2010, 18, 630-639
120. Malamas, M. S.; Robichaud, A.; Erdei, J.; Quagliato, D.; Solvibile, W.; Zhou, P.; Morris, K.; Turner, J.; Wagner, E.; Fan, K.; Olland, A.; Jacobsen, S.; Reinhart, P.; Riddell, D.; Pangalos, M. Design and synthesis of aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors with enhanced brain permeability Bioorg. Med. Chem. Lett. 2010, 20, 6597-6605
121. Malamas, M. S.; Erdei, J.; Gunawan, I.; Barnes, K.; Hui, Y.; Johnson, M.; Robichaud, A.; Zhou, P.; Yan, Y.; Solvibile, W.; Turner, J.; Fan, K. Y.; Chopra, R.; Bard, J.; Pangalos, M. N. New pyrazolyl and thienyl aminohydantoins as potent BACE1 inhibitors: exploring the S2′ region Bioorg. Med. Chem. Lett. 2011, 21, 5164-5170
122. Zhu, Z.; Sun, Z.-Y.; Ye, Y.; Voigt, J.; Strickland, C.; Smith, E. M.; Cumming, J.; Wang, L.; Wong, J.; Wang, Y.-S.; Wyss, D. F.; Chen, X.; Kuvelkar, R.; Kennedy, M. E.; Favreau, L.; Parker, E.; McKittrick, B. A.; Stamford, A.; Czarniecki, M.; Greenlee, W.; Hunter, J. C. Discovery of cyclic acylguanidines as highly potent and selective β-site amyloid cleaving enzyme (BACE) inhibitors: Part I-Inhibitor design and validation J. Med. Chem. 2010, 53, 951-965
123. Wyss, D. F.; Wang, Y. S.; Eaton, H. L.; Strickland, C.; Voigt, J. H.; Zhu, Z.; Stamford, A. W. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors Top. Curr. Chem. 2012, 317, 83-114
124. Cumming, J. N.; Smith, E. M.; Wang, L.; Misiaszek, J.; Durkin, J.; Pan, J.; Iserloh, U.; Wu, Y.; Zhu, Z.; Strickland, C.; Voigt, J.; Chen, X.; Kennedy, M. E.; Kuvelkar, R.; Hyde, L. A.; Cox, K.; Favreau, L.; Czarniecki, M. F.; Greenlee, W. J.; McKittrick, B. A.; Parker, E. M.; Stamford, A. W. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor Bioorg. Med. Chem. Lett. 2012, 22, 2444-2449
125. Edwards, P. D.; Albert, J. S.; Sylvester, M.; Aharony, D.; Andisik, D.; Callaghan, O.; Campbell, J. B.; Carr, R. A.; Chessari, G.; Congreve, M.; Frederickson, M.; Folmer, R. H.; Geschwindner, S.; Koether, G.; Kolmodin, K.; Krumrine, J.; Mauger, R. C.; Murray, C. W.; Olsson, L. L.; Patel, S.; Spear, N.; Tian, G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency J. Med. Chem. 2007, 50, 5912-5925
126. Tresadern, G.; Delgado, F.; Delgado, O.; Gijsen, H.; Macdonald, G. J.; Moechars, D.; Rombouts, F.; Alexander, R.; Spurlino, J.; Van Gool, M.; Vega, J. A.; Trabanco, A. A. Rational design and synthesis of aminopiperazinones as beta-secretase (BACE) inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 7255-7260
127. Stamford, A. W.; Scott, J. D.; Li, S. W.; Babu, S.; Tadesse, D.; Hunter, R.; Wu, Y.; Misiaszek, J.; Cumming, J. N.; Gilbert, E. J.; Huang, C.; McKittrick, B. A.; Hong, L.; Guo, T.; Zhu, Z.; Strickland, C.; Orth, P.; Voigt, J. H.; Kennedy, M. E.; Chen, X.; Kuvelkar, R.; Hodgson, R.; Hyde, L. A.; Cox, K.; Favreau, L.; Parker, E. M.; Greenlee, W. J. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Aβ reduction ACS Med. Chem. Lett. 2012, 3, 897-902
128. Gerritz, S. W.; Zhai, W.; Shi, S.; Zhu, S.; Toyn, J. H.; Meredith, J. E.; Iben, L. G.; Burton, C. R.; Albright, C. F.; Good, A. C.; Tebben, A. J.; Muckelbauer, J. K.; Camac, D. M.; Metzler, W.; Cook, L. S.; Padmanabha, R.; Lentz, K. A.; Sofia, M. J.; Poss, M. A.; Macor, J. E.; Thompson, I.; Lorin, A. Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis J. Med. Chem. 2012, 55, 9208-9223
129. Swahn, B.-M.; Kolmodin, K.; Karlström, S.; von Berg, S.; Söderman, P.; Holenz, J. r.; Berg, S.; Lindström, J.; Sundström, M.; Turek, D.; Kihlström, J.; Slivo, C.; Andersson, L.; Pyring, D.; Rotticci, D.; Ohberg, L.; Kers, A.; Bogar, K.; von Kieseritzky, F.; Bergh, M.; Olsson, L.-L.; Janson, J.; Eketjäll, S.; Georgievska, B.; Jeppsson, F.; Fälting, J. Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides J. Med. Chem. 2012, 55, 9346-9361
130. Gravenfors, Y.; Viklund, J.; Blid, J.; Ginman, T.; Karlström, S.; Kihlström, J.; Kolmodin, K.; Lindström, J.; von Berg, S.; von Kieseritzky, F.; Slivo, C.; Swahn, B.-M.; Olsson, L.-L.; Johansson, P.; Eketjäll, S.; Fälting, J.; Jeppsson, F.; Strömberg, K.; Janson, J.; Rahm, F. New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (aβ) lowering in brain J. Med. Chem. 2012, 55, 9297-9311
131. May, P. C.; Dean, R. A.; Lowe, S. L.; Martenyi, F.; Sheehan, S. M.; Boggs, L. N.; Monk, S. A.; Mathes, B. M.; Mergott, D. J.; Watson, B. M.; Stout, S. L.; Timm, D. E.; Smith LaBell, E.; Gonzales, C. R.; Nakano, M.; Jhee, S. S.; Yen, M.; Ereshefsky, L.; Lindstrom, T. D.; Calligaro, D. O.; Cocke, P. J.; Greg Hall, D.; Friedrich, S.; Citron, M.; Audia, J. E. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor J. Neurosci. 2011, 31, 16507-16516
132. Baxter, E. W.; Conway, K. A.; Kennis, L.; Bischoff, F.; Mercken, M. H.; Winter, H. L.; Reynolds, C. H.; Tounge, B. A.; Luo, C.; Scott, M. K.; Huang, Y.; Braeken, M.; Pieters, S. M.; Berthelot, D. J.; Masure, S.; Bruinzeel, W. D.; Jordan, A. D.; Parker, M. H.; Boyd, R. E.; Qu, J.; Alexander, R. S.; Brenneman, D. E.; Reitz, A. B. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead J. Med. Chem. 2007, 50, 4261-4264 (Pubitemid 47378825)
133. Madden, J.; Dod, J. R.; Godemann, R.; Kraemer, J.; Smith, M.; Biniszkiewicz, M.; Hallett, D. J.; Barker, J.; Dyekjaer, J. D.; Hesterkamp, T. Fragment-based discovery and optimization of BACE1 inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 5329-5333
134. Stachel, S. J.; Coburn, C. A.; Rush, D.; Jones, K. L.; Zhu, H.; Rajapakse, H.; Graham, S. L.; Simon, A.; Katharine Holloway, M.; Allison, T. J.; Munshi, S. K.; Espeseth, A. S.; Zuck, P.; Colussi, D.; Wolfe, A.; Pietrak, B. L.; Lai, M. T.; Vacca, J. P. Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1 Bioorg. Med. Chem. Lett. 2009, 19, 2977-2980
135. Congreve, M.; Aharony, D.; Albert, J.; Callaghan, O.; Campbell, J.; Carr, R. A.; Chessari, G.; Cowan, S.; Edwards, P. D.; Frederickson, M.; McMenamin, R.; Murray, C. W.; Patel, S.; Wallis, N. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase J. Med. Chem. 2007, 50, 1124-1132 (Pubitemid 46496313)
136. Cheng, Y.; Judd, T. C.; Bartberger, M. D.; Brown, J.; Chen, K.; Fremeau, R. T., Jr.; Hickman, D.; Hitchcock, S. A.; Jordan, B.; Li, V.; Lopez, P.; Louie, S. W.; Luo, Y.; Michelsen, K.; Nixey, T.; Powers, T. S.; Rattan, C.; Sickmier, E. A.; St Jean, D. J., Jr.; Wahl, R. C.; Wen, P. H.; Wood, S. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) J. Med. Chem. 2011, 54, 5836-5857
137. Huang, H.; La, D. S.; Cheng, A. C.; Whittington, D. A.; Patel, V. F.; Chen, K.; Dineen, T. A.; Epstein, O.; Graceffa, R.; Hickman, D.; Kiang, Y. H.; Louie, S.; Luo, Y.; Wahl, R. C.; Wen, P. H.; Wood, S.; Fremeau, R. T. Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease J. Med. Chem. 2012, 55, 9156-9169
138. Barrow, J. C.; Stauffer, S. R.; Rittle, K. E.; Ngo, P. L.; Yang, Z.; Selnick, H. G.; Graham, S. L.; Munshi, S.; McGaughey, G. B.; Holloway, M. K.; Simon, A. J.; Price, E. A.; Sankaranarayanan, S.; Colussi, D.; Tugusheva, K.; Lai, M. T.; Espeseth, A. S.; Xu, M.; Huang, Q.; Wolfe, A.; Pietrak, B.; Zuck, P.; Levorse, D. A.; Hazuda, D.; Vacca, J. P. Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase J. Med. Chem. 2008, 51, 6259-6262
139. Brodney, M. A.; Barreiro, G.; Ogilvie, K.; Hajos-Korcsok, E.; Murray, J.; Vajdos, F.; Ambroise, C.; Christoffersen, C.; Fisher, K.; Lanyon, L.; Liu, J.; Nolan, C. E.; Withka, J. M.; Borzilleri, K. A.; Efremov, I.; Oborski, C. E.; Varghese, A.; O'Neill, B. T. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors J. Med. Chem. 2012, 55, 9224-9239
140. Efremov, I. V.; Vajdos, F. F.; Borzilleri, K. A.; Capetta, S.; Chen, H.; Dorff, P. H.; Dutra, J. K.; Goldstein, S. W.; Mansour, M.; McColl, A.; Noell, S.; Oborski, C. E.; O'Connell, T. N.; O'Sullivan, T. J.; Pandit, J.; Wang, H.; Wei, B.; Withka, J. M. Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design J. Med. Chem. 2012, 55, 9069-9088
141. Oefner, C.; Binggeli, A.; Breu, V.; Bur, D.; Clozel, J. P.; D'Arcy, A.; Dorn, A.; Fischli, W.; Grüninger, F.; Güller, R.; Hirth, G.; Märki, H. P.; Mathews, S.; Müller, M.; Ridley, R. G.; Stadier, H.; Vieira, E.; Wilhelm, M.; Winkler, F. K.; Wostl, W. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? Chem. Biol. 1999, 6, 127-131 (Pubitemid 29363148)
142. Powell, N. A.; Clay, E. H.; Holsworth, D. D.; Bryant, J. W.; Ryan, M. J.; Jalaie, M.; Zhang, E.; Edmunds, J. J. Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 2371-2374 (Pubitemid 40523102)
143. Holsworth, D. D.; Cai, C.; Cheng, X. M.; Cody, W. L.; Downing, D. M.; Erasga, N.; Lee, C.; Powell, N. A.; Edmunds, J. J.; Stier, M.; Jalaie, M.; Zhang, E.; McConnell, P.; Ryan, M. J.; Bryant, J.; Li, T.; Kasani, A.; Hall, E.; Subedi, R.; Rahim, M.; Maiti, S. Ketopiperazine-based renin inhibitors: optimization of the "C" ring Bioorg. Med. Chem. Lett. 2006, 16, 2500-2504
144. Stachel, S. J.; Steele, T. G.; Petrocchi, A.; Haugabook, S. J.; McGaughey, G.; Katharine Holloway, M.; Allison, T.; Munshi, S.; Zuck, P.; Colussi, D.; Tugasheva, K.; Wolfe, A.; Graham, S. L.; Vacca, J. P. Discovery of pyrrolidine-based beta-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency Bioorg. Med. Chem. Lett. 2012, 22, 240-244
145. Study of LY2887621 in Mild Cognitive Impairment Due to Mild Alzheimer's Disease or Mild Alzheimer's Disease. http://www.clinicaltrials.gov/ct2/show/ NCT01561430?term=LY2886721&rank=6 (accessed Mar 5, 2013).
146. An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3) (EPOCH). http://www.clinicaltrials.gov/ct2/show/ NCT01739348?term=MK-8931&rank=3 (accessed Mar 5, 2013).
147. Evaluation of E2609 in Subjects with Mild Cognitive Impairment Dye to Alzheimer's Disease. http://www.clinicaltrials.gov/ct2/show/NCT01600859?term=E- 2609&rank=2 (accessed Mar 5, 2013).
148. Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers. http://www.clinicaltrials.gov/ct2/show/ NCT01348737?term=azd-3839&rank=1 (accessed Mar 5, 2013).This study has been completed.
149. Discovery Studio, version 3.5.0.12158; Accelrys, Inc.: San Diego, CA, 2012.